

## **CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention (PCI) in the Million Veterans Program**

Catherine Chanfreau-Coffinier, PhD<sup>1</sup>, Kevin A. Friede, MD<sup>2</sup>, Mary E. Plomondon, PhD<sup>3</sup>, Kyung Min Lee, PhD<sup>1</sup>, Zhenyu Lu, PhD<sup>1</sup>, Julie A. Lynch, PhD<sup>1,4</sup>, Scott L. DuVall<sup>1,4</sup>, Jason L. Vassy, MD, MPH, MS<sup>5</sup>, Stephen W. Waldo, MD<sup>3,6</sup>, John H. Cleator, MD<sup>7</sup>, Thomas M. Maddox, MD, MSc<sup>8</sup>, Daniel J. Rader, MD<sup>9</sup>, Themistocles L. Assimes, MD<sup>10</sup>, Scott M. Damrauer, MD<sup>9,11</sup>, Philip S. Tsao, MD,<sup>10</sup> Kyong-Mi Chang, MD<sup>9,11</sup> Deepak Voora, MD<sup>12</sup>, Jay Giri, MD, MPH<sup>9,11</sup> Sony Tuteja, PharmD, MS<sup>9,11</sup>; VA Million Veteran Program

<sup>1</sup> VA Salt Lake City Health Care System, Salt Lake City, UT

<sup>2</sup> Division of Cardiology, University of North Carolina School of Medicine, Chapel Hill, NC

<sup>3</sup> CART Program, Office of Quality and Patient Safety, Veterans Health Administration, Washington, DC

<sup>4</sup> Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT

<sup>5</sup> VA Boston Healthcare System, Harvard Medical School, and Brigham and Women's Hospital, Boston, MA

<sup>6</sup> Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, CO

<sup>7</sup> Centennial Heart at Skyline Medical Center, Nashville, TN

<sup>8</sup> Washington University School of Medicine in St. Louis, St. Louis, MO

<sup>9</sup> University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

<sup>10</sup> VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA

<sup>11</sup> Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

<sup>12</sup> Durham VA Healthcare System and Duke University, Durham, NC

Short title: *CYP2C19* variants and major adverse cardiac events

**Address for correspondence:**

Sony Tuteja, PharmD, MS  
3400 Spruce Street  
Maloney Building, Room 9013  
University of Pennsylvania Perelman School of Medicine  
Philadelphia, PA 19104  
215-615-8785 (phone)  
sonyt@penmedicine.upenn.edu (email)  
Sony.Tuteja@va.gov

Total word count (including title page, abstract, text, references, Tables and figure legends): 5000

## Abstract

**Background:** *CYP2C19* loss-of-function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in stable ischemic heart disease (SIHD) is unclear.

**Objectives:** Determine the association of *CYP2C19* genotype with major adverse cardiac events (MACE) after PCI for ACS or SIHD.

**Methods:** Million Veterans Program (MVP) participants age <65 years with a PCI documented in the VA Clinical Assessment, Reporting and Tracking (CART) Program between 1/1/2009 to 9/30/2017, treated with clopidogrel were included. Time to MACE defined as the composite of all-cause death, stroke or myocardial infarction within 12 months following PCI.

**Results:** Among 4,461 Veterans (mean age  $59.1 \pm 5.1$  years, 18% Black); 44% had ACS, 56% had SIHD and 29% carried a *CYP2C19* LOF allele. 301 patients (6.7%) experienced MACE while being treated with clopidogrel, 155 (7.9%) in the ACS group and 146 (5.9%) in the SIHD group. Overall, MACE was not significantly different between LOF carriers vs. noncarriers (adjusted hazard ratio [HR] 1.18, confidence interval [95%CI] 0.97-1.45,  $p=0.096$ ). Among patients presenting with ACS, MACE risk in LOF carriers versus non-carriers was numerically higher (HR 1.30, 95%CI 0.98-1.73,  $p=0.067$ ). There was no difference in MACE risk in patients with SIHD (HR 1.09, 95%CI 0.82-1.44;  $p=0.565$ ).

**Conclusions:** *CYP2C19* LOF carriers presenting with ACS treated with clopidogrel following PCI experienced a numerically greater elevated risk of MACE events. *CYP2C19* LOF genotype is not associated with MACE among patients presenting with SIHD.

**Key words:** *CYP2C19* genotype, clopidogrel, percutaneous coronary intervention, acute coronary syndrome, stable ischemic heart disease.

**Abbreviation list:**

CART	Clinical Assessment, Reporting, and Tracking database
CYP2C19	Cytochrome P450 2C19
BARC	Bleeding Academic Research Consortium
LOF	Loss of function
MACE	Major adverse cardiac events
MVP	Million Veteran Program
PCI	Percutaneous coronary intervention
SIHD	Stable ischemic heart disease
STEMI	ST-segment elevation myocardial infarction

## Introduction

Combination therapy with a P2Y<sub>12</sub> receptor inhibitor and aspirin is routinely prescribed to prevent major adverse cardiac events (MACE) in patients undergoing percutaneous coronary intervention (PCI).<sup>1, 2</sup> Clopidogrel, a prodrug that is biotransformed into its active metabolite predominantly by the hepatic cytochrome P450 2C19 (CYP2C19) enzyme, is the most common antiplatelet drug prescribed in the setting of both acute coronary syndromes (ACS) and stable ischemic heart disease (SIHD).<sup>3-5</sup> Approximately 30% of Whites and 60% of East Asians carry *CYP2C19* loss-of-function (LOF) alleles (\*2-\*8), resulting in a decreased antiplatelet effect and an increased risk of MACE.<sup>6-10</sup>

Consensus guidelines published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend alternative antiplatelet therapy with prasugrel or ticagrelor in LOF carriers undergoing PCI as the effectiveness of these drugs is not impacted by the variants.<sup>11</sup> These recommendations are not always followed due to the higher costs of the drugs and the increased risk of bleeding associated with the alternative agents.<sup>4, 12-14</sup> However, the CPIC guidelines do not make a distinction between ACS and nonACS indications in their recommendations even though there are limited contemporary data evaluating the impact of *CYP2C19* variants in SIHD. Both observational and randomized controlled trial data show a strong association of *CYP2C19* LOF alleles and elevated MACE risk in patients treated with clopidogrel following PCI in patients with ACS.<sup>9, 15-17</sup> This association has been conflicting or null in patients with SIHD.<sup>18-20</sup>

Additional data are needed in real-world cohorts of diverse patients that are not well represented in RCTs, including those with SIHD. The purpose of this study was to determine: 1) the association of *CYP2C19* LOF variants with MACE in participants receiving clopidogrel following PCI in the Veterans Health Administration (VA), 2) the association of the *CYP2C19* increased function variant with major bleeding events, and 3) whether these associations differed by indication for PCI (ACS vs. SIHD). The Million Veteran Program (MVP) is an ongoing, prospective genetic biorepository that recruits patients from 63 facilities within the VA, the largest integrated healthcare system in the US.<sup>21</sup> The VA's integration of longitudinal electronic health records (EHR) data with laboratory test results and pharmacy records makes the MVP an ideal platform for pharmacogenetic analyses.

## Methods

All relevant data are available in the main paper and supplemental data. Individual data cannot be shared publicly according to the Data Access Policy of the Million Veteran Program in the VA Office of R&D in Veterans Health Administration. The MVP received ethical and study protocol approval by the Veterans Affairs Central Institutional Review Board. Informed consent has been obtained from all participants. Each additional study was also approved by the local institutional review board. This project was also approved by the MVP Publication and Presentation Committee. For the full methods of this study, please refer to the Supplemental Methods.

## Results

### *Patient characteristics*

A total of 17,060 MVP participants underwent a PCI documented by the CART Program from 2009-2017. After applying the exclusion criteria, the final cohort was 4,461 (Supplemental figure 1). The cohort was 98% male, 76% white, with a mean age of 59.1  $\pm$ 5.1 years (Table 1). Common comorbidities included hypertension (90%), dyslipidemias (86%), and diabetes (53%). The indication for PCI was ACS for 44% of the cohort and SIHD for 56%. The median follow-up time was 595 days (interquartile [IQR] range 584, 606) with no difference by PCI indication. The median (IQR) exposure to clopidogrel in the whole cohort was 383 days (301, 465) and was not different by PCI indication [ACS, 382 (305, 459) vs. SIHD, 383 (298, 468)].

Overall, 29% of the cohort (n=1,301) carried at least one loss-of-function (LOF) allele. Baseline comorbidities and discharge medications were well balanced between patients with and without LOF, although there were more Black participants among LOF carriers (Table 1). Baseline demographics by *CYP2C19* metabolizer groups, which included 1,743 NM (39%), 1,417 RM/UM (32%), 1,016 IM/PM (23%) and 285 IM/\*17 (6%), are found in Supplemental table 5. Detailed breakdown of *CYP2C19* diplotypes by ancestry is shown in Supplemental table 6.

### *Major Adverse Cardiovascular Events*

In the overall cohort, 301 patients (6.7%) experienced MACE while being treated with clopidogrel, 155 (7.9%) in the ACS group and 146 (5.9%) in the SIHD group (Table 2, Supplemental table 7). The incidence of MACE in the overall cohort was not significantly different between LOF carriers and non-carriers (adjusted hazard ratio [aHR] 1.18, 95% confidence interval (CI) 0.97-1.45, p=0.096) (Table 2, Figure 1A,

Supplemental figure 2) or by *CYP2C19* metabolizer group (Supplemental figure 3). However, ACS was strongly associated with MACE (Supplemental figure 2), and stratified analyses by PCI indication revealed a non-significantly higher risk of MACE in LOF carriers vs. non-carriers among patients with ACS (aHR 1.30, 95% CI 0.98-1.73;  $p=0.067$ , Table 2, Figure 1B, Supplemental figure 4). There was no impact of genotype in patients with SIHD (aHR 1.09, 95%CI 0.82-1.44,  $p=0.565$ ) (Table 2, Figure 1C, Supplemental figure 5).

### *Bleeding events*

At least one high risk factor for bleeding was found in 765 (17%) participants (Supplemental table 8), and 153 (3.4%) participants experienced a major bleeding event while on clopidogrel (Supplemental table 9). In the overall cohort we observed a non-significantly reduced rate of bleeding events among *CYP2C19* LOF carriers vs. non-carriers (aHR 0.73, 95% CI 0.50-1.4,  $p\text{-value}=0.096$ ) (Table 3, Supplemental table 10). To investigate the contribution of *CYP2C19* increased function allele (*\*17*) towards bleeding events, we examined bleeding by *CYP2C19* metabolizer groups. The risk of bleeding was not increased among patients who carry at least one increased function copy [i.e., RM/UM and IM/*\*17* (Figure 2, Table 3)]. In contrast, the bleeding risk was significantly lower among IM/PM compared to NM (aHR 0.57, 95% CI 0.35-0.91,  $p\text{-value}=0.018$ , Supplemental figure 6).

## **Discussion**

MVP participants age <65 years who were *CYP2C19* LOF carriers treated with clopidogrel following PCI did not experience a statistically increased risk of MACE.



There was no impact of genotype in patients undergoing PCI for SIHD but among those with a PCI indication of ACS the risk of MACE demonstrated a numerically elevated, though marginally non-significant, 30% increased risk among LOF carriers versus noncarriers. The presence of the *CYP2C19* increased function \*17 allele did not increase the risk of bleeding events, however LOF carrier status was associated with reduced risk of major bleeding events. These results have important implications for the role of genotyping to manage patients with stable coronary syndromes.

Our findings are largely consistent with previous observational studies, meta-analyses and recent prospective trials reporting an increased risk of MACE in *CYP2C19* LOF carriers treated with clopidogrel.<sup>9, 17, 22-24</sup> The largest RCT, TAILOR-PCI, including 5,302 PCI patients, supported that prospective *CYP2C19* genotyping reduced the composite endpoint of CV death, MI, stroke, stent thrombosis and severe recurrent ischemia at 12 months in LOF carriers compared to LOF carriers in the control arm where all patients received clopidogrel (4.0% vs. 5.9%, respectively, [HR, 0.66; 95%CI, 0.43-1.02; p=0.06]). In a recent meta-analysis of 15,949 patients from 7 RCTs including TAILOR-PCI, predominantly focused on the ACS population (98%), the risk of ischemic events was significantly reduced in LOF carriers receiving ticagrelor or prasugrel (7.0%) versus clopidogrel (10.3%; HR, 0.70; 95%CI 0.59-0.83), while there was no such reduction in non-carriers (HR, 1.0; 95%CI 0.8-1.25). Most TAILOR-PCI participants presented with ACS with only 14% having SIHD and the authors did not examine the impact of genotyping in this subgroup.

A stratified analysis by PCI indication was conducted by Kim et al and found that patients with two *CYP2C19* LOF variants had a significantly higher risk of MACE in

patients presenting with acute MI (hazard ratio, 2.88; 95% confidence interval, 1.27–6.53;  $P=0.011$ ).<sup>18</sup> However, this finding was not seen in patients presenting with stable angina. A recent meta-analysis conducted to evaluate the association of *CYP2C19* LOF alleles and MACE risk in patients with SIHD and found an increased risk of MACE in LOF carriers.<sup>19</sup> However, upon further inspection of the 21 studies they included in their analysis, eight studies also included patients with non-ST-elevation ACS (NSTEMI) and unstable angina (UA), and the indication for PCI could not be ascertained for three studies, limiting the overall conclusions of their analysis. More recently, an analysis by the IGNITE consortium in 3,342 patients, showed a decrease in MACE for LOF carriers presenting with ACS prescribed alternative therapy compared with LOF carriers prescribed clopidogrel (HR, 0.49; 95%CI 0.32-0.76,  $p=0.001$ ) but no reduction in MACE in patients presenting with SIHD (HR, 1.02; 95%CI 0.44-2.36,  $p=0.96$ ), indicating that prospective genotyping may be more important in patients undergoing PCI for ACS.<sup>20</sup> In our analysis, the SIHD group included those without documentation of ACS (i.e., STEMI, NSTEMI, and UA). We found that the presence of *CYP2C19* LOF alleles in clopidogrel treated patients undergoing PCI for SIHD was not associated with an increased risk for MACE. These results support that a genotype-guided approach to antiplatelet prescribing may not be warranted in patients presenting with SIHD. In contrast to these previous studies, the definition of MACE in our study did not include repeat vascularization, an endpoint that is more prone to bias, and this conservative definition is therefore a strength of our study.

Our study included a more diverse real-world patient population with ~20% African ancestry individuals and more patients with a higher rate of comorbid conditions. The

clinical variables of age, BMI, CKD, diabetes along with *CYP2C19* genotype have been identified as independent predictors of high platelet reactivity on clopidogrel and adverse clinical outcomes.<sup>25-27</sup> In comparison to TAILOR-PCI participants, those in MVP had a higher prevalence of these comorbidities including higher BMI (31.6 vs. 26.9 kg/m<sup>2</sup>), and more diabetes (53% vs. 28%) and CKD (19% vs. 12%). Future analyses in larger cohorts are warranted to evaluate the role of *CYP2C19* genotype in those with CKD or obesity/diabetes.

We did not find an association between the *CYP2C19* \*17 allele and bleeding events. While several studies report an association of the \*17 allele with decreased risk for MACE<sup>28</sup> and/or increased risk of bleeding,<sup>29</sup> this association is usually attenuated when accounting for the correlation due to linkage disequilibrium between the \*2 and \*17 alleles.<sup>30</sup> While the presence of the \*17 allele, by itself, is of limited utility in predicting MACE or bleeding events in patients receiving clopidogrel,<sup>31, 32</sup> it may be useful as a component of a polygenic risk score to predict MACE.<sup>33</sup> We also found a reduced rate of major bleeding among *CYP2C19* LOF carriers, which is likely related to diminished bioactivation of clopidogrel.

Several limitations to our analysis should be noted. Sample is limited to Veterans who received treatment within the VHA with a PCI documented in the CART data. We only included Veterans <65 years of age at the time of the procedure; this restriction aimed to address a possible lack in tracking clinical events in the VA electronic medical record for Veterans over age 65 who are eligible to receive care non-VA through Medicare. A gap in event documentation was supported by the observation of lower than expected frequency of MACE events among older patients (Supplemental Figure

7). As the risk of MACE increases with age<sup>25-27</sup>, a gap in capturing events in older patients would likely have abrogated the association of LOF alleles with the MACE outcome in the overall analyses. Future studies should aim to link Medicare and MVP data and document MACE occurring outside the VA among older patients. Despite the relatively large size of the sample, it is possible that the analyses lacked sufficient power enough to detect a significant association. We did not include a comparison group consisting of LOF carriers treated with prasugrel or ticagrelor, which would provide additional information about the potential reduction of MACE risk with these agents. At the time of cohort identification, there were few participants receiving these agents that also had genotype data available within MVP. For our bleeding analysis, we only counted severe bleeding events based on strict criteria including admission to the hospital or emergency department and objective measures of bleeding such as receipt of blood transfusion or defined changes in hemoglobin. However, patients frequently discontinue antiplatelet agents based on nuisance bleeding, which cannot be captured adequately using EHR data.

## Conclusions

MVP participants age <65 years who are *CYP2C19* LOF carriers treated with clopidogrel experienced a non-significantly higher risk of MACE when presenting with acute coronary syndromes. There was no impact of *CYP2C19* genotype in patients receiving PCI for stable ischemic heart disease. The presence of the *CYP2C19* \*17 increased-function allele was not associated with an increased risk of bleeding events.

## Acknowledgements

### Sources of Funding:

Funding/support: Funding for MVP003 was provided by I01-BX003362 (K.M.C., P.S.T.). This work was supported using resources and facilities of the Department of Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457. SMD is supported by IK2-CX001780. ST is supported by K23HL143161.

**Author disclosures:** JAL and SLD report grants from Alnylam Pharmaceuticals, Inc, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Biodesix, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from IQVIA Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from MDxHealth, grants from Merck & Co., Inc., grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. TMM is an advisor for Myia Labs, for which his employer is receiving equity compensation in the company. SMD receives research support to the University of Pennsylvania from RenalytixAI and Novo Nordisk (in-kind), as well as personal fees from Calico Labs, all outside the current work. JG reports serving on advisory boards and receiving research funding to the institution from Abiomed, Boston Scientific, Abbott Vascular, Recor Medical, Inari Medical, and Astra Zeneca. JG reports equity interest in Endovascular Engineering.

**Disclaimer:** This publication does not represent the views of the Department of Veterans Affairs or the United States Government.

## References

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK and Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Journal of the American College of Cardiology*. 2011;58:e44-122.
2. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK and Smith SC, Jr. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. *Circulation*. 2016;134:e123-55.
3. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T and Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. *Drug Metab Dispos*. 2010;38:92-9.
4. Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J and Groeneveld PW. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016. *JAMA internal medicine*. 2018;178:943-950.
5. Karve AM, Seth M, Sharma M, LaLonde T, Dixon S, Wohns D and Gurm HS. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). *The American journal of cardiology*. 2015;115:1502-6.
6. Gurbel PA, Becker RC, Mann KG, Steinhubl SR and Michelson AD. Platelet Function Monitoring in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2007;50:1822-1834.
7. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, 2nd, Lachno DR, Salazar D and Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. *Journal of thrombosis and haemostasis : JTH*. 2007;5:2429-36.
8. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W and Gurbel PA. Association of cytochrome P450 2C19 genotype

with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *Jama*. 2009;302:849-57.

9. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD and Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *Jama*. 2010;304:1821-30.

10. Cavallari LH, Lee CR, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardani AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Eley AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG and Johnson JA. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *JACC Cardiovascular interventions*. 2018;11:181-191.

11. Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM, Gaedigk A, Caudle KE, Klein TE, Johnson JA and Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. *Clin Pharmacol Ther*. 2022;112:959-967.

12. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM and Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001-15.

13. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A and Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045-57.

14. Basra SS, Wang TY, Simon DN, Chiswell K, Virani SS, Alam M, Nambi V, Denktas AE, Deswal A, Bozkurt B, Ballantyne CM, Peterson ED and Jneid H. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. *Journal of the American Heart Association*. 2018;7:e008125.

15. Sorich MJ, Rowland A, McKinnon RA and Wiese MD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: A meta-analysis. *Circulation: Cardiovascular Genetics*. 2014;7:895-902.

16. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH and Becker RC. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel

for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet (London, England)*. 2010;376:1320-8.

17. Pereira NL, Rihal C, Lennon R, Marcus G, Shrivastava S, Bell MR, So D, Geller N, Goodman SG, Hasan A, Lerman A, Rosenberg Y, Bailey K, Murad MH and Farkouh ME. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y<sub>12</sub> Inhibitor Therapy: A Meta-Analysis. *JACC Cardiovascular interventions*. 2021;14:739-750.
18. Kim HS, Chang K, Koh YS, Park MW, Choi YS, Park CS, Oh M, Kim EY, Shon JH, Shin JG and Seung KB. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. *Circulation Cardiovascular genetics*. 2013;6:514-21.
19. Biswas M and Kali SK. Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis. *Cardiovascular drugs and therapy*. 2021.
20. Beitelshes AL, Thomas CD, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, Tuteja S, Limdi NA, Lee JC, Duarte JD, Kreutz RP, Skaar TC, Coons JC, Giri J, McDonough CW, Rowland R, Stevenson JM, Thai T, Vesely MR, Wellen JT, Johnson JA, Winterstein AG, Cavallari LH and Lee CR. CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. *Journal of the American Heart Association*. 2022;11:e024159.
21. Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, Whitbourne S, Deen J, Shannon C, Humphries D, Guarino P, Aslan M, Anderson D, LaFleur R, Hammond T, Schaa K, Moser J, Huang G, Muralidhar S, Przygodzki R and O'Leary TJ. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *Journal of Clinical Epidemiology*. 2016;70:214-223.
22. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM and Ten Berg JM. A Genotype-Guided Strategy for Oral P2Y<sub>12</sub> Inhibitors in Primary PCI. *N Engl J Med*. 2019;381:1621-1631.
23. Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K and Rihal C. Effect of Genotype-Guided Oral P2Y<sub>12</sub> Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. *Jama*. 2020;324:761-771.
24. Cavallari LH, Lee CR, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsev AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner



- AR, Winterstein AG and Johnson JA. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *JACC Cardiovascular interventions*. 2017.
25. Angiolillo DJ, Capodanno D, Danchin N, Simon T, Bergmeijer TO, Ten Berg JM, Sibbing D and Price MJ. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. *JACC Cardiovascular interventions*. 2020;13:606-617.
26. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA and Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. *Journal of the American College of Cardiology*. 2007;49:1505-16.
27. Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, O'Connor SA, Bellemain-Appaix A, Barthélémy O, Beygui F, Collet JP and Montalescot G. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. *Eur Heart J*. 2012;33:1241-9.
28. Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A and Kastrati A. Protective effect of the CYP2C19 \*17 polymorphism with increased activation of clopidogrel on cardiovascular events. *American heart journal*. 2010;160:506-12.
29. Saiz-Rodríguez M, Romero-Palacián D, Villalobos-Vilda C, Caniego JL, Belmonte C, Koller D, Bárcena E, Tategón M and Abad-Santos F. Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure. *Clin Pharmacol Ther*. 2019;105:661-671.
30. Lewis JP, Stephens SH, Horenstein RB, O'Connell JR, Ryan K, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Mitchell BD and Shuldiner AR. The CYP2C19\*17 variant is not independently associated with clopidogrel response. *Journal of thrombosis and haemostasis : JTH*. 2013;11:1640-6.
31. Gross L, Trenk D, Jacobshagen C, Krieg A, Gawaz M, Massberg S, Baylacher M, Aradi D, Stimpfle F, Hromek J, Vogelgesang A, Hadamitzky M, Sibbing D and Geisler T. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy. *Thrombosis and haemostasis*. 2018;118:1656-1667.
32. Lee CR, Thomas CD, Beitelshes AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, Gong Y, Kreutz RP, McDonough CW, Stevenson JM, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA and Cavallari LH. Impact of the CYP2C19\*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *Clin Pharmacol Ther*. 2021;109:705-715.
33. Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE and Shuldiner AR. Pharmacogenomic polygenic response

score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. *European heart journal Cardiovascular pharmacotherapy*. 2020;6:203-210.

Figure 1. Time to major adverse cardiac event (MACE) in carriers of *CYP2C19* loss-of-function allele. A) in whole analytic sample (n=4,461), B) among patients presenting with acute coronary syndromes (ACS) (n=1,968), and C) among patients with stable ischemic heart disease (SIHD) (n=2,493). Cumulative incidence of MACE events using a Kaplan Meier model stratified by groups. MACE: major adverse cardiac event defined as myocardial infarction, stroke, and all-cause death; LOF: carrying at least 1 *CYP2C19* loss of function allele; nonLOF: without *CYP2C19* LOF alleles.

Figure 2. Time to bleeding event by *CYP2C19* metabolizer group in overall cohort (n=4,461). Cumulative incidence of bleeding events using a Kaplan Meier model stratified by groups. IM/PM: *CYP2C19* intermediate and poor metabolizers; RM/UM: *CYP2C19* rapid and ultra-rapid metabolizers; IM/\*17: *CYP2C19* intermediate also carrying one or two copies of the \*17 variant; NM: *CYP2C19* normal metabolizers.

Table 1. Baseline and procedural characteristics stratified by *CYP2C19* LOF carrier status

	All (n=4,461)	<i>CYP2C19</i> LOF (n=1,301)	<i>CYP2C19</i> NonLOF (n=3,160)	P-value *
Age (years)	59.1 ± 5.1	58.8 ± 5.3	59.3 ± 5.0	0.009
Male	4356 (97.6)	1268 (97.5)	3088 (98.0)	0.683
Race				
White	3401 (76.2)	956 (73.5)	2445 (77.4)	0.021
Black	823 (18.4)	267 (20.5)	556 (17.6)	
Other	237 (5.3)	78 (6.0)	159 (5.0)	
Ethnicity Hispanic/Latino	256 (5.7)	70 (5.4)	186 (5.9)	0.693
BMI (kg/m <sup>2</sup> )	31.6 ± 6.4	31.6 ± 6.4	31.6 ± 6.5	0.755
Ever smoker	2835 (63.6)	808 (62.1)	2027 (64.1)	0.437
PCI Indication				
Stable CAD	2493 (55.9)	748 (57.5)	1745 (55.2)	0.175
ACS	1968 (44.1)	553 (42.5)	1415 (44.8)	
STEMI	298 (6.7)	102 (7.8)	196 (6.2)	0.054
Non-STEMI	694 (15.6)	205 (15.8)	489 (15.5)	0.848
Unstable angina	1019 (22.8)	261 (20.1)	758 (24.0)	0.005
Bare metal stent	600 (13.4)	186 (14.3)	414 (13.1)	0.310
PCI post MVP enrollment	1841 (41.3)	560 (43.0)	1281 (40.5)	0.131
Medical History				
Hypertension	4018 (90.1)	1157 (88.9)	2861 (90.5)	0.115
Diabetes	2380 (53.4)	674 (51.8)	1706 (54.0)	0.196
Dyslipidemia	3846 (86.2)	1120 (86.1)	2726 (86.3)	0.913
Heart failure	1301 (29.2)	377 (29.0)	924 (29.2)	0.889
CKD	851 (19.1)	252 (19.4)	599 (19.0)	0.781
PVD	1155 (25.9)	324 (24.9)	831 (26.3)	0.353
Atrial fibrillation	485 (10.9)	133 (10.2)	352 (11.1)	0.401
Prior MI	1881 (42.2)	528 (40.6)	1353 (42.8)	0.181
Prior CABG	627 (14.1)	182 (14.0)	445 (14.1)	0.973
Prior PCI	1288 (28.9)	371 (28.5)	917 (29.0)	0.764
Prior TIA	350 (7.8)	106 (8.1)	244 (7.7)	0.675
Prior stroke	218 (4.9)	69 (5.3)	149 (4.7)	0.452
Discharge meds at PCI				
Aspirin	4050 (90.8)	1178 (90.5)	2872 (90.9)	0.764
Statin	3991 (89.5)	1166 (89.6)	2825 (89.4)	0.866
ACEi or ARB	3434 (77.0)	984 (75.6)	2450 (77.5)	0.184
Beta-blocker	4016 (90.0)	1170 (89.9)	2846 (90.1)	0.937

Anticoagulant	818 (18.3)	227 (17.4)	591 (18.7)	0.346
Proton pump inhibitor	1796 (40.3)	551 (42.4)	1245 (39.4)	0.073

Data are presented as n (%) or mean  $\pm$  standard deviation. \* p-value for comparison by carrier status

ACEi, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney disease; LOF, *CYP2C19* loss-of-function allele carriers; MI, myocardial infarction; NSTEMI, non-ST-Elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI ST-Elevation myocardial infarction; TIA, transient ischemic attack

Table 2. Cox proportional hazard model for MACE in overall cohort and stratified by PCI indication

MACE outcome by <i>CYP2C19</i> LOF carrier status	Event rate	Unadjusted HR (95% confidence interval)	p-value	Adjusted HR (95% confidence interval)	p-value
Overall cohort (n=4,461)*					
LOF (n=1,301)	99 (7.6%)	1.20 (0.94-1.52)	0.141	1.18 (0.97-1.45)	0.096
nonLOF (n=3,160)	202 (6.4%)	Reference		Reference	
ACS (n=1,968)†					
LOF (n=553)	54 (9.8%)	1.39 (0.998-1.93)	0.052	1.30 (0.98-1.73)	0.067
nonLOF (n=1,415)	101 (7.1%)	Reference		Reference	
SIHD (n=2,493)†					
LOF (n=748)	45 (6.0%)	1.04 (0.73-1.48)	0.83	1.09 (0.82-1.44)	0.565
nonLOF (n=1,745)	101 (5.8%)	Reference		Reference	

\*adjusted for indication for PCI (ACS vs. SIHD), age at PCI, race, use of bare metal stent, history of diabetes, chronic kidney disease, prior myocardial infarction, stroke, TIA, peripheral vascular disease, congestive heart failure, prior PCI, time of enrollment into MVP, with clopidogrel as a time varying exposure.

† adjusted for age at PCI, race, use of bare metal stent, history of diabetes, chronic kidney disease, prior myocardial infarction, stroke, TIA, peripheral vascular disease, congestive heart failure, prior PCI, time of enrollment into MVP, with clopidogrel as a time varying exposure.

Table 3. Cox proportional hazard model for bleeding events in overall cohort by *CYP2C19* loss of function carrier status and *CYP2C19* metabolizer group

BARC 3 or 5 bleeding events in overall cohort (n=4,461)	Event rate N(%)	Unadjusted HR (95% confidence interval)	p-value	Adjusted HR* (95% confidence interval)	p-value
LOF carrier status					
LOF (n=1,301)	36 (2.8%)	0.74 (0.51-1.08)	0.116	0.73 (0.50-1.40)	0.096
nonLOF (n=3,160)	117 (3.7%)	Reference			
<i>CYP2C19</i> metabolizer group					
IM/PM (n=1,106)	23 (2.3%)	0.56 (0.35-0.91)	0.018	0.57 (0.35-0.91)	0.018
RM/UM (n=1,417)	48 (3.4%)	0.85 (0.59-1.23)	0.39	0.86 (0.60-1.25)	0.43
IM/*17 (n=285)	13 (4.6%)	1.15 (0.63-2.08)	0.65	1.09 (0.60-1.97)	0.78
NM (n=1,743)	69 (4.0%)	Reference		Reference	

\*Adjusted for indication for PCI (ACS vs. SIHD), age at PCI, race, use of bare metal stent, receipt of aspirin, major risk for bleeding, time of enrollment into MVP.

IM/PM: *CYP2C19* intermediate and poor metabolizers; RM/UM: *CYP2C19* rapid and ultra-rapid metabolizers; IM/\*17: *CYP2C19* intermediate metabolizer also carrying one or two copies of the \*17 variant; NM: *CYP2C19* normal metabolizers.





